Stockscreener 앱 받기
1.08
1.89%
0.02
시간 외 거래:
1.08
전일 마감가:
$1.06
열려 있는:
$1.0799
하루 거래량:
146.12K
Relative Volume:
0.78
시가총액:
$12.55M
수익:
-
순이익/손실:
$-10.93M
주가수익비율:
-0.7511
EPS:
-1.4378
순현금흐름:
$-10.72M
1주 성능:
+1.89%
1개월 성능:
+0.93%
6개월 성능:
+0.93%
1년 성능:
-55.00%
1일 변동 폭
$1.07
$1.125
1주일 범위
$1.055
$1.125
52주 변동 폭
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
명칭
Phio Pharmaceuticals Corp
전화
(508) 767-3861
주소
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.08 | 12.78M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2020-08-05 | 개시 | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp 주식(PHIO)의 최신 뉴스
PHIO Q1 2026 Earnings: EPS Miss Widens as Clinical-Stage Biotech Continues R&D InvestmentEarnings Sentiment Score - newsline.com
PHIO Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Reports ResultsProfit Inflection Point - newsline.com
Number of shareholders of Phio Pharmaceuticals Corp. – MUN:44R1 - TradingView
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as R&D Spending IntensifiesEarnings Growth Forecast - newsline.com
Phio Pharmaceuticals Slides 2.6% as Selling Pressure PersistsForce Index - newsline.com
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Biotech Reports No Revenue - The Legal Advocate
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.17Reversal Setup Alerts - newsline.com
Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech - Bez Kabli
PHIO Q1 2026 Earnings: EPS Misses Estimates Amid Continued Clinical Trials FocusRevenue Beat Analysis - The Legal Advocate
Skin cancer treatment PH-762: Phio live Q&A session May 28 - Stock Titan
Phio Pharmaceuticals Holds Steady Near Support Levels; PHIO Stock Consolidates in Narrow RangeMA Cross Alert - The Legal Advocate
PHIO Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D InvestmentInvestor Earnings Call - thelegaladvocate.com
PHIO Q1 2026 Earnings: EPS Misses Estimates as Research-Focused Biotech Maintains Development Pace - newsline.com
PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026 - TMX Newsfile
Phio Pharmaceuticals (PHIO) Q1 2026 Results Miss Estimates — EPS $-0.34 vs $-0.24Product Mix - newser.com
Phio Pharmaceuticals Corp.Common Stock (NQ:PHIO) - FinancialContent
PHIO Should I Buy - Intellectia AI
TradingKey - TradingKey
Skin cancer drug hits 65% response; doctor, CEO to discuss what's next - Stock Titan
MSN Money - MSN
Why Phio Pharmaceuticals (PHIO) could be the turning point you've been waiting for (-0.87%) 2026-05-07Fast Rising Picks - newser.com
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Phio Pharmaceuticals (NASDAQ: PHIO) boosts PH-762 spending as Q1 2026 loss grows - Stock Titan
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - TMX Newsfile
Skin cancer drug trial wraps at Phio, FDA submission targets Q2 - Stock Titan
PHIO Q1'26 Earnings: EPS estimate is (0.23) USD - TradingView
Is Phio Pharmaceuticals (PHIO) stock forming a trend channel | Q4 2025: EPS Tops ViewsStrategic Review - Newser
Cancer drug developer Phio sets April 29 live Q&A on clinical progress - Stock Titan
Phio Pharmaceuticals (PHIO) Stock Resistance Rejection (Modest Decline) 2026-04-20Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 - TMX Newsfile
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 - TMX Newsfile
PHIO: RNA immunotherapy shows strong tumor clearance and safety, advancing to next clinical phase - TradingView
Phio Pharmaceuticals to Discuss 'Nobel Prize Winning Science' for Skin Cancer Treatment - National Today
EPS Watch: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Trade Ideas & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
User - The Chronicle-Journal
How do market conditions affect Phio Pharmaceuticals (PHIO) Stock | Price at $1.24, Up 2.48%Demand Zone - newsline.com
Form 8-KCurrent report - ADVFN
Phio Pharmaceuticals Corp (PHIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Phio Pharmaceuticals Corp 주식 (PHIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
2.60%
0.94%
자본화:
|
볼륨(24시간):